07:00 , May 23, 2016 |  BC Week In Review  |  Company News

BioDelivery, Collegium deal

BioDelivery granted Collegium exclusive, U.S. rights to pain drug Onsolis fentanyl buccal soluble film. Collegium expects to launch the product in mid-2017. BioDelivery will receive $2.5 million up front and is eligible for up...
08:00 , Feb 9, 2015 |  BC Week In Review  |  Company News

BioDelivery, Meda deal

Meda returned North American rights to Onsolis fentanyl buccal soluble film to BioDelivery. Meda received rights to Onsolis in 2007. BioDelivery plans to re-partner the drug in the U.S. and will work with the...
07:00 , Apr 14, 2014 |  BC Week In Review  |  Company News

Meda, Valeant Pharmaceuticals sales and marketing update

This quarter, Meda and Valeant will terminate their joint commercialization ventures in Canada, Mexico and Australia. Meda said the companies can in the longer term "better explore opportunities" in the markets as separate entities. Valeant...
07:00 , Aug 5, 2013 |  BC Week In Review  |  Clinical News

Painkyl regulatory update

BioDelivery said that Taiwan approved Painkyl fentanyl to manage breakthrough cancer pain in opioid-tolerant adult patients with cancer. The approval triggers a $300,000 milestone payment to BioDelivery from TTY, which has exclusive rights to develop...
07:00 , May 20, 2013 |  BC Week In Review  |  Clinical News

Onsolis regulatory update

BioDelivery disclosed in its 1Q13 earnings that it and Meda submitted a proposal to FDA in March to relaunch pain drug Onsolis fentanyl in the U.S., with a potential launch slated for next half. Last...
07:00 , Oct 22, 2012 |  BC Week In Review  |  Company News

BioDelivery, MonoSol Rx neurology, drug delivery news

The U.S. Patent and Trademark Office resolved two reexaminations of MonoSol's U.S. Patent Nos. 7,425,292 and 7,357,891, covering its PharmFilm technology for preparing drug-containing films. In February and March, the PTO respectively granted reexamination and...
07:00 , Oct 22, 2012 |  BC Week In Review  |  Company News

BioDelivery, Meda sales and marketing update

BioDelivery said partner Meda launched Breakyl fentanyl buccal film in Germany. The launch triggered a $2.5 million milestone payment from Meda to BioDelivery under a 2006 deal. The price per film is €7.71 ($9.99)....
07:00 , May 28, 2012 |  BC Week In Review  |  Company News

BioDelivery, Meda deal

BioDelivery received a $2.5 million milestone payment from Meda under a 2006 deal granting Meda exclusive European rights to develop and commercialize Breakyl fentanyl. The payment was triggered by the pricing approval and registration...
07:00 , Mar 19, 2012 |  BC Week In Review  |  Company News

Aveva Drug Delivery Systems Inc., BioDelivery, MonoSol Rx, Meda neurology, drug delivery news

The U.S. District Court for the District of New Jersey granted BioDelivery's motion to stay proceedings in MonoSol's patent infringement suit against Aveva, BioDelivery and Meda, pending the resolution of the U.S. Patent and Trademark...
07:00 , Mar 19, 2012 |  BC Week In Review  |  Company News

BioDelivery sales and marketing update

BioDelivery said the U.S. relaunch of pain drug Onsolis fentanyl is being postponed so that two appearance issues raised by FDA can be addressed. The agency noted the formation of microscopic crystals and a...